1. Generics Bulletin
  2. >>Market Intelligence
  3. >>Company Rankings

Consolidation And COVID See Industry Top 10 Rankings Rewritten

Viatris Merger And Pandemic Disruption Shake Up Industry Leaders

 
• By Dave Wallace

After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, the leaders of the pack in the Generics Bulletin Top 50 have once again seen significant changes in 2021.

Generics Bulletin Top 50 2021
Sales of the top 10 generics and biosimilars players were shaken up in 2020 • Source: Alamy/Informa

In the wake of what can only be described as an extraordinary year, Generics Bulletin’s annual ranking of the world’s top 50 generics and biosimilars companies has seen major disruption, as companies grapple with the impact of the COVID-19 pandemic on demand patterns and the supply chain at the same time as a major merger has reshaped one of the off-patent industry’s biggest players.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Company Rankings

Generics Bulletin’s Top 50 Ranking For 2024

 
• By Dave Wallace

This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.

The Generics Bulletin Top 50, Part Three: Firms Fall Out Of Final Grouping

 
• By Dave Wallace

In the third instalment of this year’s Generics Bulletin Top 50, we look at some of the firms that have been eliminated from the bottom of our table as others have entered the picture.

The Generics Bulletin Top 50, Part Two: Major Shifts Bring Ups And Downs For Mid-Ranked Players

 
• By Dave Wallace

In the second part of Generics Bulletin’s Top 50, we see some companies rising up the rankings of generics and biosimilars players worldwide, passing others that are moving in the opposite direction.

The Generics Bulletin Top 50, Part One: Top Ten Ranking Conceals Changes For Industry Leaders

 
• By Dave Wallace

A deceptively familiar top 10 of generics and biosimilars industry leaders this year belies the significant evolutions seen for major off-patent players over the past 12 months. We reveal the changes under the surface in the first instalment of this year’s Generics Bulletin Top 50.

More from Market Intelligence

UK Memantine Prices Spike In November

 
• By Dave Wallace

Dementia treatment memantine saw the steepest rise in its UK trade price in November, according to the latest figures from WaveData.

Apixaban Prices Begin To Correct After Months Of UK Rises

 
• By Dave Wallace

After a few months of steep UK price rises for apixaban generics, October saw a correction as average prices headed in the opposite direction, the latest figures from WaveData reveal.

Latuda, Other Generics Cleared In 2022 Helped Generate Nearly $19bn In Savings, US FDA Says

 
• By Derrick Gingery

Generics of the schizophrenia treatment Latuda generated more than $4bn in savings a year after their 2022 approval, according to an FDA study.